Table 2 Antiretroviral drugs and QTc prolongation
Drug | Cases (n=32) | Controls (n=64) | p |
|---|---|---|---|
Zidovudine | |||
Yes | 11 | 12 | 0.15 |
No | 21 | 52 | |
Lamivudine | |||
Yes | 17 | 28 | 0.5 |
No | 15 | 36 | |
Tenofovir | |||
Yes | 15 | 35 | 0.6 |
No | 17 | 29 | |
Emtricitabine | |||
Yes | 4 | 20 | 0.08 |
No | 28 | 44 | |
Emtricitabine+tenofovir | |||
Yes | 4 | 20 | 0.08 |
No | 28 | 44 | |
Zidovudine+lamivudine | |||
Yes | 7 | 11 | 0.8 |
No | 25 | 53 | |
Didanosine | |||
Yes | 4 | 4 | 0.4 |
No | 28 | 60 | |
Abacavir | |||
Yes | 3 | 4 | 0.6 |
No | 29 | 60 | |
Efavirenz | |||
Yes | 11 | 20 | 0.9 |
No | 21 | 44 | |
Nevirapine | |||
Yes | 3 | 6 | 1 |
No | 29 | 58 | |
Atazanavir | |||
Yes | 6 | 16 | 0.6 |
No | 26 | 48 | |
Fosamprenavir | |||
Yes | 2 | 2 | 0.6 |
No | 30 | 62 | |
Lopinavir/ritonavir | |||
Yes | 2 | 5 | 1 |
No | 30 | 59 | |